Information  X 
Enter a valid email address

Lipoxen PLC (XEN)

  Print      Mail a friend

Friday 17 October, 2008

Lipoxen PLC

Additional Listing

RNS Number : 9979F
Lipoxen PLC
17 October 2008

Lipoxen PLC

('Lipoxen' or 'the Company')

Additional listing

London, UK, 17 October 2008 - Lipoxen PLC (AIM:LPX) a bio-pharmaceutical company specialising in the development of high value differentiated biologicals, vaccines and oncology drugs, announces that application has been made to AIM, a market of the London Stock Exchange plc, for the admission of 135,658 ordinary shares of 0.5p each (the 'New Ordinary Shares').

The New Ordinary Shares are being admitted pursuant to the exercise of options under the Lipoxen Plc Unapproved Share Option Plan.

It is expected that dealing in the New Ordinary Shares, which will rank pari passu in all respects with the existing issued share capital of the Company, will commence on 21 October 2008.


Lipoxen PLC

M. Scott Maguire, Chief Executive Officer

Colin Hill, Finance Director

+44 (0)20 7691 3583 

Teathers Ltd (nominated adviser)

Shaun Dobson / Claes Spång 

+44 (0)20 7426 9000

Citigate Dewe Rogerson


+44 (0)20 7638 9571

David Dible / Heather Keohane

This information is provided by RNS
The company news service from the London Stock Exchange